HC Wainwright Reiterates “Buy” Rating for BioCardia (NASDAQ:BCDA)

BioCardia (NASDAQ:BCDA)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They presently have a $25.00 price objective on the stock.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of BioCardia in a research note on Monday, April 20th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $25.00.

BioCardia Stock Performance

Shares of NASDAQ BCDA opened at $0.92 on Tuesday. The stock has a 50 day moving average price of $1.08 and a 200 day moving average price of $1.21. BioCardia has a 52 week low of $0.84 and a 52 week high of $2.45. The stock has a market capitalization of $10.47 million, a PE ratio of -1.01 and a beta of 0.51.

BioCardia (NASDAQ:BCDA) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.04). As a group, research analysts forecast that BioCardia will post -0.71 EPS for the current year.

Hedge Funds Weigh In On BioCardia

A number of hedge funds have recently added to or reduced their stakes in BCDA. Cetera Investment Advisers bought a new position in BioCardia during the 2nd quarter worth $40,000. Geode Capital Management LLC boosted its holdings in shares of BioCardia by 70.4% during the 4th quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock valued at $83,000 after acquiring an additional 27,263 shares in the last quarter. Finally, DRW Securities LLC acquired a new stake in shares of BioCardia during the 4th quarter valued at $72,000. Institutional investors own 20.57% of the company’s stock.

BioCardia Company Profile

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.